These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38975147)

  • 1. Development and evaluation of a disulfidoptosis-related lncRNA index for prognostication in clear cell renal cell carcinoma.
    Guan R; Zuo Y; Du Q; Zhang A; Wu Y; Zheng J; Shi T; Wang L; Wang H; Yu N
    Heliyon; 2024 Jun; 10(12):e32294. PubMed ID: 38975147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
    Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y
    Front Genet; 2023; 14():1039813. PubMed ID: 36755568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Model to Predict Prognosis of Renal Cell Clear Cell Carcinoma Based on 3 Angiogenesis-related Long Non-coding RNAs.
    Chen G; Zhang T; Li F; Cui C; Huang Z; Gou X; Song Y; Li Y
    J Cancer; 2024; 15(11):3481-3494. PubMed ID: 38817877
    [No Abstract]   [Full Text] [Related]  

  • 4. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
    Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H
    Front Genet; 2022; 13():938259. PubMed ID: 35910212
    [No Abstract]   [Full Text] [Related]  

  • 6. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elaboration and validation of a prognostic signature associated with disulfidoptosis in lung adenocarcinoma, consolidated with integration of single-cell RNA sequencing and bulk RNA sequencing techniques.
    He D; Tang H; Yang X; Liu X; Zhang Y; Shi J
    Front Immunol; 2023; 14():1278496. PubMed ID: 37965333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data.
    Zeng JH; Lu W; Liang L; Chen G; Lan HH; Liang XY; Zhu X
    J Transl Med; 2019 Aug; 17(1):281. PubMed ID: 31443717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
    Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
    Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
    Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B
    Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Validation of a Ferroptosis-Related Long Non-Coding RNA (FRlncRNA) Signature to Predict Survival Outcomes and the Immune Microenvironment in Patients With Clear Cell Renal Cell Carcinoma.
    Zhou Z; Yang Z; Cui Y; Lu S; Huang Y; Che X; Yang L; Zhang Y
    Front Genet; 2022; 13():787884. PubMed ID: 35350243
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Ferroptosis-Related LncRNAs Signatures Associated with Tumor Immune Infiltration and Experimental Validation in Clear Cell Renal Cell Carcinoma.
    Chen X; Tu J; Ma L; Huang Y; Yang C; Yuan X
    Int J Gen Med; 2022; 15():3215-3235. PubMed ID: 35342303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma.
    Lin H; Qu L; Chen G; Zhang C; Lu L; Chen Y
    Eur J Med Res; 2023 Jul; 28(1):236. PubMed ID: 37452355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a cancer driver gene-associated lncRNA signature for prognostic prediction and immune response evaluation in clear cell renal cell carcinoma.
    Pan J; Hu D; Huang X; Li J; Zhang S; Li J
    Transl Cancer Res; 2024 Jul; 13(7):3418-3436. PubMed ID: 39145048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma.
    Zhang Z; Tang Y; Liu Y; Zhuang H; Lin E; Xie L; Feng X; Tian K; Zeng J; Liu J; Yu Y
    J Immunol Res; 2021; 2021():9921466. PubMed ID: 34368371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of CCNB2 and a novel lncRNAs-related risk model predict prognosis in clear cell renal cell carcinoma.
    Ren C; Wang Q; Xu Z; Pan Y; Wang S; Liu X
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):64. PubMed ID: 38300330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosome-related lncRNA score: A value-based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma.
    Yang Z; Zhang X; Zhan N; Lin L; Zhang J; Peng L; Qiu T; Luo Y; Liu C; Pan C; Hu J; Ye Y; Jiang Z; Liu X; Sun M; Zhang Y
    Cancer Med; 2024 Jun; 13(11):e7308. PubMed ID: 38808948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.